InMed Pharmaceuticals Inc. (NASDAQ: INM) has appointed Netta Jagpal as its new Chief Financial Officer and Corporate Secretary, effective February 20, 2024, marking a significant change in its executive leadership. Jagpal, a seasoned financial expert with over two decades of experience primarily in the biotech sector, will be taking over from Jonathan Tegge, who served as Interim CFO.
Prior to joining InMed, Jagpal held key positions at D-Wave Systems Inc. (NYSE: QBTS), Zymeworks Inc. (NYSE: NASDAQ: ZYME), and Angiotech Pharmaceuticals, Inc. (NASDAQ: ANP), as well as experience at Ernst & Young.
Jagpal is a Chartered Professional Accountant accredited by the Institute of Chartered Accountants of British Columbia and holds a Bachelor of Business Administration degree from Simon Fraser University.
InMed expressed appreciation for Mr. Tegge’s contributions and anticipates his continued involvement with the organization.
Eric A. Adams, President and CEO of InMed, expressed confidence in Jagpal’s abilities, highlighting her extensive background in finance and accounting leadership roles, which he believes will be instrumental in driving the company’s pharmaceutical drug development and commercial endeavors forward.
Have you read?
Ranked: Here’s who buys the most weapons from the United States.
Ranking: Richest Golfers in the World, 2023.
These Largest Cities Will Face Extreme Climate Change Threats.
These All-American Football Movies Inspired CEOs and Management Consultants The Most.
These Are Most Disliked Companies in America, 2023.
Report: Countries That Attract the Most International Migrants.
Add CEOWORLD magazine to your Google News feed.
Follow CEOWORLD magazine headlines on: Google News, LinkedIn, Twitter, and Facebook.
Copyright 2024 The CEOWORLD magazine. All rights reserved. This material (and any extract from it) must not be copied, redistributed or placed on any website, without CEOWORLD magazine' prior written consent. For media queries, please contact: info@ceoworld.biz
